Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNX NASDAQ:INMD NASDAQ:MDXG NYSEAMERICAN:STXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$21.13-5.4%$20.19$8.89▼$26.66$971.12MN/A941,691 shs553,523 shsINMDInMode$15.27-1.1%$14.84$13.14▼$19.85$975.95M2.09821,261 shs1.25 million shsMDXGMiMedx Group$6.71+2.0%$7.05$5.59▼$10.14$973.57M1.73705,705 shs580,697 shsSTXSStereotaxis$3.15+3.3%$2.89$1.54▼$3.59$277.77M1.65598,586 shs616,874 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics-5.42%-4.52%-16.52%+60.56%+2,112,999,900.00%INMDInMode-1.10%+1.46%+2.76%+8.30%-8.29%MDXGMiMedx Group+1.98%-5.49%-3.73%-0.15%+14.90%STXSStereotaxis+3.28%-11.76%+11.70%+32.35%+65.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$21.13-5.4%$20.19$8.89▼$26.66$971.12MN/A941,691 shs553,523 shsINMDInMode$15.27-1.1%$14.84$13.14▼$19.85$975.95M2.09821,261 shs1.25 million shsMDXGMiMedx Group$6.71+2.0%$7.05$5.59▼$10.14$973.57M1.73705,705 shs580,697 shsSTXSStereotaxis$3.15+3.3%$2.89$1.54▼$3.59$277.77M1.65598,586 shs616,874 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics-5.42%-4.52%-16.52%+60.56%+2,112,999,900.00%INMDInMode-1.10%+1.46%+2.76%+8.30%-8.29%MDXGMiMedx Group+1.98%-5.49%-3.73%-0.15%+14.90%STXSStereotaxis+3.28%-11.76%+11.70%+32.35%+65.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.69Moderate Buy$24.4415.69% UpsideINMDInMode 2.00Hold$18.2119.24% UpsideMDXGMiMedx Group 2.50Moderate Buy$12.0078.84% UpsideSTXSStereotaxis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest STXS, INMD, MDXG, and BBNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025INMDInModeCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$14.00 ➝ $16.0010/10/2025INMDInModeNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold10/8/2025BBNXBeta BionicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025INMDInModeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025MDXGMiMedx GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/1/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Buy$18.00 ➝ $26.0010/1/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$18.00 ➝ $26.009/29/2025INMDInModeZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/27/2025BBNXBeta BionicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025INMDInModeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025MDXGMiMedx GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$65.12M14.11N/AN/A($5.72) per share-3.69INMDInMode$394.82M2.44$1.80 per share8.47$10.12 per share1.51MDXGMiMedx Group$348.88M2.85$0.34 per share19.86$1.31 per share5.12STXSStereotaxis$26.92M10.66N/AN/A$0.07 per share45.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/AINMDInMode$181.27M$2.476.188.39N/A44.50%18.38%16.35%11/5/2025 (Estimated)MDXGMiMedx Group$42.42M$0.2131.9520.97N/A8.84%23.03%17.09%10/29/2025 (Estimated)STXSStereotaxis-$24.05M-$0.28N/AN/AN/A-73.43%-440.00%-50.62%11/10/2025 (Estimated)Latest STXS, INMD, MDXG, and BBNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/10/2025Q3 2025STXSStereotaxis-$0.06N/AN/AN/A$8.43 millionN/A11/5/2025Q3 2025INMDInMode$0.32N/AN/AN/A$88.05 millionN/A10/29/2025Q3 2025MDXGMiMedx Group$0.07N/AN/AN/A$94.74 millionN/A7/30/2025Q2 2025INMDInMode$0.50$0.47-$0.03$0.42$98.45 million$95.60 million7/30/2025Q2 2025MDXGMiMedx Group$0.06$0.10+$0.04$0.06$90.79 million$98.61 million7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AINMDInModeN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ASTXSStereotaxisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/A14.6813.79INMDInModeN/A9.608.58MDXGMiMedx Group0.084.393.90STXSStereotaxisN/A1.060.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AINMDInMode68.04%MDXGMiMedx Group79.15%STXSStereotaxis45.35%Insider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/AINMDInMode6.92%MDXGMiMedx Group1.70%STXSStereotaxis17.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.47 millionN/AN/AINMDInMode48063.21 million58.84 millionOptionableMDXGMiMedx Group870147.96 million145.44 millionOptionableSTXSStereotaxis13091.07 million74.89 millionNot OptionableSTXS, INMD, MDXG, and BBNX HeadlinesRecent News About These CompaniesStereotaxis wins CE mark for Synchrony system, submits to FDAOctober 15 at 2:44 PM | massdevice.comStereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath LabsOctober 15 at 7:32 AM | globenewswire.comSTXS Partners With CardioFocus to Boost Robotic Pulsed Field AblationOctober 14 at 1:55 PM | zacks.comStereotaxis, CardioFocus collaborate to advance robotic PFA technologyOctober 13 at 12:25 PM | msn.comStereotaxis, CardioFocus collab on robotic PFA for cardiac arrhythmiasOctober 13 at 12:25 PM | massdevice.comStereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac ArrhythmiasOctober 13 at 7:34 AM | globenewswire.comStereotaxis (STXS) Announces First Robotic MAGiC Sweep Catheter Procedure at Deborah Heart and Lung CenterSeptember 23, 2025 | finance.yahoo.comSTXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic SystemSeptember 23, 2025 | zacks.comStereotaxis announces procedures using Genesis at Erasmus Medical CenterSeptember 22, 2025 | msn.comStereotaxis Genesis robot used in first procedures in NetherlandsSeptember 22, 2025 | massdevice.comStereotaxis At Inflection Point: Why I Choose To HoldSeptember 22, 2025 | seekingalpha.comErasmus Medical Center Advances Cardiovascular Care with Genesis Robotic SystemSeptember 22, 2025 | globenewswire.comISRG's SP Stapler: A Game Changer for Colorectal and Thoracic Procedures?September 3, 2025 | msn.comSTXS Launches First U.S. Robotic HD Mapping With MAGiC SweepSeptember 3, 2025 | msn.comSTXS Launches First U.S. Robotic HD Mapping With MAGiC SweepSeptember 3, 2025 | zacks.comFirst US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep CatheterSeptember 2, 2025 | globenewswire.comStereotaxis to Present at Upcoming Investor ConferencesSeptember 2, 2025 | globenewswire.comStereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 2025August 28, 2025 | markets.businessinsider.comStereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025August 28, 2025 | globenewswire.comStereotaxis, Inc. (STXS) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTXS, INMD, MDXG, and BBNX Company DescriptionsBeta Bionics NASDAQ:BBNX$21.13 -1.21 (-5.42%) As of 10/15/2025 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.InMode NASDAQ:INMD$15.27 -0.17 (-1.10%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$15.30 +0.03 (+0.20%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.MiMedx Group NASDAQ:MDXG$6.71 +0.13 (+1.98%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$6.72 +0.00 (+0.07%) As of 10/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Stereotaxis NYSEAMERICAN:STXS$3.15 +0.10 (+3.28%) Closing price 10/15/2025 04:10 PM EasternExtended Trading$3.16 +0.02 (+0.48%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
